NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS
05 Juli 2023 - 7:00PM
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS
POSITION BY EXERCISING “BSPCE” WARRANTS
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS
POSITION BY EXERCISING “BSPCE” WARRANTS
NFL BIOSCIENCES (Euronext Growth
Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company
developing botanical drugs for the treatment of addictions, has
been informed that 50,000 BSPCE company
founder warrants (“BSPCE warrants”) held by Mr Bruno Lafont, Chief
Operating Officer and co-founder of NFL Biosciences, have been
exercised, giving him the right to subscribe 500,000 new shares,
enabling him to further strengthen his
position in the capital of the company
that he co-founded in 2006. Bruno
Lafont now holds 8.86% of NFL Biosciences’ capital, compared with
4.18% previously.
The 50,000 BSPCE 2018 warrants held by Mr Lafont
were exercised in full on July 5, 2023, before their maturity date
of July 2, 2025. They enabled him to subscribe 500,000 new shares
at a price of €0.10, generating a €50,000 cash contribution for NFL
Biosciences.
Since 2006, Bruno Lafont has been in charge of
structuring and developing NFL Biosciences, which he co-founded.
Within NFL Biosciences’ leadership team, he is specifically
responsible for managing the implementation of clinical trials and
the company’s scientific activities.
In connection with his own personal financial
management, before exercising his BSPCE warrants, Mr Lafont sold
100,000 NFL Biosciences shares on the Euronext Growth Paris market
at an average price of €2.6. These transactions were filed today
with the AMF, in accordance with stock market regulations.
Following these operations, Bruno Lafont now holds 718,029 shares
(1,039,807 shares on a diluted basis).
When he exercised his BSPCE warrants, Mr
Lafont declared: “I am proud of the years dedicated to
developing NFL Biosciences and our fight to treat addictions, and
particularly NFL-101, for smoking cessation. I have chosen to
further strengthen my position in its capital because I am
confident that our CESTO 2 clinical trial will be able to provide a
first demonstration of efficacy for the regulatory authorities,
which would, without a doubt, enable NFL Biosciences to achieve a
change in scale. Independently from our ambitions, for personal
financial reasons, I intend to sell a maximum of 100,000 shares
over the next 12 months”.
Following the exercising of the BSPCE warrants
held by Mr Lafont, NFL Biosciences’ capital has increased to
8,106,769 shares, compared with 7,606,769 before they were
exercised. Its potential capital now represents 9,177,057 shares,
with a potential dilution of 13%, compared with 39% at June 25,
2023.
The detailed characteristics of the capital and
potential capital before these BSPCE warrants were exercised are
presented in the 2022 Annual Financial Report, published on April
28, 2023 and available on the Company’s website under “Documents”:
https://www.nflbiosciences.com.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorder.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - 04 11
93 76 67 Agence
Calyptus – nflbiosciences@calyptus.net - 01 53 65 68 68
-
NFLBiosciences_CP_Exercice-BSPCE-Bruno-Lafont_20230705_EN_DEF
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
